Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]

<p>Abstract</p> <p>Background</p> <p>High-dose interferon alfa-2b (IFNalfa-2b), according to the ECOG 1684 schedule, is the only approved adjuvant treatment for stage III melanoma patients by the FDA and EMEA. However, the risk/benefit profile has been questioned limiting its world-wide use. In the...

Descripción completa

Detalles Bibliográficos

Autores principales:	Ridolfi Ruggero, Naglieri Emanuele, Dalla Palma Maurizio, Paccagnella Adriano, Guida Michele, Romanini Antonella, Del Bianco Paola, Chiarion-Sileni Vanna, Silvestri Barbara, Michiara Maria, De Salvo Gian Luca
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	BMC 2006-02-01
Colección:	BMC Cancer
Acceso en línea:	http://www.biomedcentral.com/1471-2407/6/44
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!